Compare BAND & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | OLMA |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 771.9M | 863.0M |
| IPO Year | 2017 | 2020 |
| Metric | BAND | OLMA |
|---|---|---|
| Price | $51.99 | $11.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $24.50 | ★ $44.89 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $204,113,000.00 | N/A |
| Revenue This Year | $15.16 | N/A |
| Revenue Next Year | $6.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $12.50 | $4.12 |
| 52 Week High | $75.98 | $36.26 |
| Indicator | BAND | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 50.29 |
| Support Level | $14.27 | $7.79 |
| Resistance Level | $75.98 | $11.54 |
| Average True Range (ATR) | 5.25 | 0.73 |
| MACD | -2.22 | 0.29 |
| Stochastic Oscillator | 14.74 | 83.21 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of its revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.